SFXN5 Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP6403a
Background:
Parkinson's disease (PD) is a multifactorial disease that appears to arise from the effects of both genetic and environmental influences. The known genetic factors include multiple genes that have been identified in related parkinsonian syndromes, as well as alpha-synuclein. Genes associated with either PD or Parkinson-related disorders include parkin, DJ-1, ubiquitin C-terminal hydrolase isozyme L1 (UCH-L1), nuclear receptor-related factor 1 (NURR1), and alpha-synuclein. SFXN5 has been known to locate at the Park3 region of chromosome 2p (PARK3; OMIM 602404). However, sequence analysis of 2p13 linked individuals affected with PD did not reveal any potentially pathogenic mutations within SFXN5, suggesting SFXN5 may not correspond to PARK3 (Lockhart et al.). Search for Park3 gene is still under development and HtrA2 is suspected to be one candidate.
Other Names:
Sideroflexin-5, SFXN5
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6403a was selected from the N-term region of human SFXN5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: SFXN5 {ECO:0000303|PubMed:12039050, ECO:0000312|HGNC:HGNC:16073}
Gene ID: 94097
Primary Accession: Q8TD22
Other Accession: NP_653180
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Parkinson's disease (PD) is a multifactorial disease that appears to arise from the effects of both genetic and environmental influences. The known genetic factors include multiple genes that have been identified in related parkinsonian syndromes, as well as alpha-synuclein. Genes associated with either PD or Parkinson-related disorders include parkin, DJ-1, ubiquitin C-terminal hydrolase isozyme L1 (UCH-L1), nuclear receptor-related factor 1 (NURR1), and alpha-synuclein. SFXN5 has been known to locate at the Park3 region of chromosome 2p (PARK3; OMIM 602404). However, sequence analysis of 2p13 linked individuals affected with PD did not reveal any potentially pathogenic mutations within SFXN5, suggesting SFXN5 may not correspond to PARK3 (Lockhart et al.). Search for Park3 gene is still under development and HtrA2 is suspected to be one candidate.
Other Names:
Sideroflexin-5, SFXN5
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6403a was selected from the N-term region of human SFXN5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: SFXN5 {ECO:0000303|PubMed:12039050, ECO:0000312|HGNC:HGNC:16073}
Gene ID: 94097
Primary Accession: Q8TD22
Other Accession: NP_653180
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review